Morphing the Model
Drug delivery companies hold on to technologies longer with ultimate goal of commercializing proprietary products themselves
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
March 7, 2005 Cover
Volume 83, Issue 10
Drug delivery companies hold on to technologies longer with ultimate goal of commercializing proprietary products themselves
Credit:
Pharmaceuticals
No-prep Mass Spec
New atmospheric pressure ionization method is suitable for security and defense applications
Trapping Cells and Organelles
Technique selectively encapsulates single cells and subcellular structures
-
Patent Pending
A series of Japanese patent disputes raises questions about employee patent rights
-
Robbing Peter to Pay Paul
Pentagon seeks ways to fund chemical weapons destruction and meet a treaty deadline
-
A Vision Realized
DSM Chairman Elverding reflects on completion of revamp program
ADVERTISEMENT
Edwin Moses
Biotech executive's career experiences mirror evolution of the industry
